Dulce Gomez Trujillo
Research Subjects
Dulce Gomez Trujillo has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Carolina Morales-Ochoa
1 shared publication- Emanuel Guajardo-Correa
Cátedra de Cardiología y Medicina Vascular, Escuela de Medicina y Ciencias de la Salud, Tecnológico de Monterrey, Hospital Zambrano-Hellion, San Pedro Garza-García, Nuevo León, 66278, México | Institute for Obesity Research, Tecnológico de Monterrey, Hospital Zambrano-Hellion, San Pedro Garza-García, Nuevo León, 66278, México | Tecnologico de Monterrey, Unidad Cardiometabólica Miguel y Betty Schwarz. Hospital Zambrano-Hellion, San Pedro Garza-García, NL, 66278, Mexico
1 shared publication Gerardo García-Rivas
Tecnológico de Monterrey
1 shared publicationGuillermo Torre-Amione
1 shared publicationHipolito Miranda
1 shared publication- Héctor Chapoy-Villanueva
Tecnológico de Monterrey
1 shared publication
Latest Publications
- Open Access
- 13 October 2026
- Published by Springer Nature in Research Square
Cannabidiol attenuates kidney injury and mitochondrial calcium dysregulation in experimental cardiorenal syndrome.
Cardiorenal syndrome (CRS) is characterized by bidirectional heart–kidney dysfunction in which oxidative stress, inflammation, and mitochondrial dysfunction drive progressive kidney injury, but the role of mitochondrial calcium (Ca²⁺) handling through the mitochondrial calcium uniporter (MCU) complex remains unclear. Here we show, in a mouse model of CRS induced by angiotensin II and L-NAME in male mice (C57BL/6), that renal mitochondria exhibit increased MCU expression, reduced Ca²⁺ retention capacity, and greater susceptibility to Ca²⁺-induced permeability transition, alongside impaired respiration, reduced PGC-1α and TFAM expression, oxidative stress, and inflammatory activation. Cannabidiol (CBD) attenuates renal dysfunction and structural injury, restores mitochondrial respiratory capacity and complex I activity, normalizes MCU expression, and partially improves mitochondrial Ca²⁺ handling, independently of blood pressure reduction. These findings identify MCU-dependent mitochondrial Ca²⁺ dysregulation as a candidate mechanism linking mitochondrial dysfunction to renal injury in CRS, and a potential target for CBD’s nephroprotective effects.
- 13 October 2026
- Published by Springer Nature in Research Square
Open AccessCannabidiol attenuates kidney injury and mitochondrial calcium dysregulation in experimental cardiorenal syndrome.
Cardiorenal syndrome (CRS) is characterized by bidirectional heart–kidney dysfunction in which oxidative stress, inflammation, and mitochondrial dysfunction drive progressive kidney injury, but the role of mitochondrial calcium (Ca²⁺) handling through the mitochondrial calcium uniporter (MCU) complex remains unclear. Here we show, in a mouse model of CRS induced by angiotensin II and L-NAME in male mice (C57BL/6), that renal mitochondria exhibit increased MCU expression, reduced Ca²⁺ retention capacity, and greater susceptibility to Ca²⁺-induced permeability transition, alongside impaired respiration, reduced PGC-1α and TFAM expression, oxidative stress, and inflammatory activation. Cannabidiol (CBD) attenuates renal dysfunction and structural injury, restores mitochondrial respiratory capacity and complex I activity, normalizes MCU expression, and partially improves mitochondrial Ca²⁺ handling, independently of blood pressure reduction. These findings identify MCU-dependent mitochondrial Ca²⁺ dysregulation as a candidate mechanism linking mitochondrial dysfunction to renal injury in CRS, and a potential target for CBD’s nephroprotective effects.